112 related articles for article (PubMed ID: 24724258)
1. [TOPCAT study. Heart failure: spironolactone disappoints in the "problem patient"].
Overbeck P
MMW Fortschr Med; 2013 Dec; 155(21-22):26. PubMed ID: 24724258
[No Abstract] [Full Text] [Related]
2. Natriuretic peptide-guided therapy for heart failure: ready for "battle" or too "scarred" by the challenges of trial design?
Maisel A
J Am Coll Cardiol; 2009 Dec; 55(1):61-4. PubMed ID: 20117365
[No Abstract] [Full Text] [Related]
3. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
[TBL] [Abstract][Full Text] [Related]
4. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Ferreira JP; Santos M; Almeida S; Marques I; Bettencourt P; Carvalho H
Eur J Intern Med; 2014 Jan; 25(1):67-72. PubMed ID: 24070521
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of amino-terminal pro-brain natriuretic peptide levels in the HPS and the CORONA study.
Cleland JG; Squire I; Ng L
J Am Coll Cardiol; 2008 Sep; 52(13):1104-5. PubMed ID: 18848145
[No Abstract] [Full Text] [Related]
7. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial.
Lainchbury JG; Troughton RW; Frampton CM; Yandle TG; Hamid A; Nicholls MG; Richards AM
Eur J Heart Fail; 2006 Aug; 8(5):532-8. PubMed ID: 16829189
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-guided treatment of heart failure: still waiting for a definitive answer.
Troughton RW; Frampton CM; Nicholls MG
J Am Coll Cardiol; 2010 Dec; 56(25):2101-4. PubMed ID: 21144970
[No Abstract] [Full Text] [Related]
9. Hospital management of heart failure: improvement but still room for improvement at discharge..
Cohen-Solal A
Arch Cardiovasc Dis; 2008 Apr; 101(4):202-3. PubMed ID: 18654093
[No Abstract] [Full Text] [Related]
10. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
Feola M; Menardi E; Ribichini F; Vado A; Deorsola A; Ferrero V; Visconti G; Milanese U; Uslenghi E
Med Sci Monit; 2003 Aug; 9(8):CR341-5. PubMed ID: 12942029
[TBL] [Abstract][Full Text] [Related]
11. Can natriuretic peptides help identify heart failure patients for whom statins are beneficial?
Daniels LB; Barrett-Connor E
J Am Coll Cardiol; 2009 Nov; 54(20):1860-1. PubMed ID: 19892236
[No Abstract] [Full Text] [Related]
12. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
[TBL] [Abstract][Full Text] [Related]
13. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin and cardiovascular continuum when time is important.
Barrios V; Escobar C
J Am Coll Cardiol; 2010 Apr; 55(15):1645-6; author reply 1646. PubMed ID: 20378088
[No Abstract] [Full Text] [Related]
15. [Determination of brain natriuretic peptide levels and its N-terminal fragment for the evaluation of renal replacement therapies efficiency in patients with decompensated chronic heart failure].
Tabak'ian EA; Zaruba AIu; Rogoza AN; Ataullakhanova DM; Kukharchuk VV
Ter Arkh; 2010; 82(8):24-9. PubMed ID: 20873241
[TBL] [Abstract][Full Text] [Related]
16. Brain natriuretic peptide-guided management of chronic heart failure: first do no harm.
Richards AM
Eur J Heart Fail; 2013 Aug; 15(8):832-4. PubMed ID: 23821462
[No Abstract] [Full Text] [Related]
17. Spironolactone for heart failure: spiraling out of control.
Geraci JM; Knowlton AA
Chest; 2000 Dec; 118(6):1522-3. PubMed ID: 11115427
[No Abstract] [Full Text] [Related]
18. Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Ishii C
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S19-22. PubMed ID: 12688391
[TBL] [Abstract][Full Text] [Related]
19. [Value of diuretics and aldosterone antagonists in the treatment of heart failure].
Schwinger RH
Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S40-7. PubMed ID: 10535046
[No Abstract] [Full Text] [Related]
20. [Natriuretic peptides in the therapy of acute decompensated heart failure].
Gassanov N; Caglayan E; Erdmann E; Er F
Dtsch Med Wochenschr; 2011 Aug; 136(34-35):1738-43. PubMed ID: 21877307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
